Arecor Therapeutics plc

("Arecor" or the "Company")

NON-EXECUTIVE DIRECTOR BOARD CHANGE

-    Dr Alan E Smith, CBE, FRS, Ph.D., to retire as he steps down from Non-Executive Director role on Arecor's Board

Cambridge, UK, 2 June 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that Dr Alan Smith, who has served as a Non-Executive Director of Arecor for more than 17 years, has informed the Company that he will not seek re-election and will retire from the Board at the forthcoming annual general meeting to be held today, 2 June 2025.

Throughout his time at Arecor, Dr Smith has provided invaluable scientific and strategic guidance as the Company has evolved from its early stages to a clinical-stage company, underpinned by its proprietary Arestat™ technology platform.

Andrew Richards, Non-Executive Chair of Arecor, said: "I would like to express our sincere gratitude to Alan for his many years of dedicated service on the Board and the exceptional scientific expertise and critical insights he has brought to Arecor. His guidance to the team and the Board has been instrumental in helping Arecor advance as a company. We wish him all the best in his retirement."

Alan Smith, Non-Executive Director, Arecor, said: "I joined Arecor's Board because I was so impressed with the company's understanding of the science behind formulation, an area I know to be neglected at many biotech companies. I am proud of what the company has achieved and confident in its eventual success as it advances its promising pipeline of therapeutics that has the potential to significantly improve patient care."

-ENDS-

For more information, please contact:

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.  For further details please see our website, www.arecor.com